News
-
2020-10 16MORE
3D Medicines' New Laboratory Building for Translational Medicine Center Came into Service and R&D Capabilities Continued to Grow
Shanghai, October 16, 2020 – 3D Medicines announced that a new laboratory building for Translational Medicine Center came into service, and the R&D capabilities continued to grow.
-
2020-10 08MORE
Focusing on the R&D and Commercialization of Immuno-oncology Drugs, 3D Medicines Raised $140 Million in First-round Financing
October 8, 2020，3D Medicines, Inc., a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated immuno-oncology drugs, announced the completion of the first-round of financing after the spin-off, the total size of the round of financing of 140 million U.S. dollars, or about 970 million yuan.
-
2020-09 21MORE
3D Medicines Reached a Collaboration Agreement with GenScript ProBio
Shanghai, September 21, 2020 – 3D Medicines Inc., a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated immuno-oncology drugs, and GenScript ProBio, a leading CDMO (contract development and manufacturing organization) in China with one-stop antibody drugs R&D solutions, announced a collaboration agreement on stages including pre-clinical discovery and pharmacological research of biological macromolecule drug projects.
-
2020-09 20MORE
3D Medicines Announced the Publication of
September 20, 2020, Beijing, China – 3D Medicines announced the publication of "the results of a single arm, pivotal, multicenter, phase II study to evaluate the efficacy and safety of Envafolimab (KN035) monotherapy in dMMR/MSI-H advanced cancer" on Chinese Society of Clinical Oncology (CSCO) annual meeting. Envafolimab (KN035) is a next-generation PD-L1 antibody, on which 3D Medicines Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and Simcere Pharmaceuticals reached a strategic collaboration.
